Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check3 days agoChange DetectedB-cell chronic lymphocytic leukemia was added to the list of conditions described on the study page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision labels updated from v3.4.3 to v3.5.0. No visible changes to study details, eligibility criteria, or outcomes.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision: v3.4.2 has been added. The funding-lapse notice and the prior Revision: v3.4.1 have been removed.SummaryDifference0.4%

- Check60 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's status was added, with guidance to refer to opm.gov for updates; the page revision label was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check68 days agoChange DetectedGlossary toggle added; capitalization adjusted for labels (e.g., ‘Last Update Submitted that Met QC Criteria’ and ‘No FEAR Act Data’); revision updated to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.